IMPROVING ACCESS TO
INNOVATIVE HEALTH TECHNOLOGIES

ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and ReimbursemenT models to Appraise INnovative health technologies) addresses the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe.

Find out how you can benefit!

FAQ

What is ASCERTAIN?

ASCERTAIN is a project aimed at helping people get better access to new health technologies such as medicines, medical devices, and tests. The project is creating a tool that can be used by decision-makers to understand the cost and value of these new health technologies.

What is the ASCERTAIN policy support tool?

The tool will be accessible to everyone on the internet and will have information about the cost and value of these new health technologies. It will also consider the impact on the environment. The project will work with patients, industry, policy makers, and payers to make sure the tool is good quality and useful.

Why is the affordability of innovative health technologies a challenge?

It’s a challenge for many countries in the European Union to afford new health technologies because they are often expensive and not everyone has equal access to them. This tool will help decision-makers understand how much these technologies should cost and how much they can save the healthcare system.

What are the goals of ASCERTAIN?

The goal of ASCERTAIN is to make it easier for people to understand the cost and value of new health technologies. The tool will be open to everyone and will be able to be adapted to different countries’ needs. It will have information about the cost and value of these technologies and will encourage “greener” production.

News

ASCERTAIN NEWSLETTER 1

Dear Readers,

The affordability of newly approved innovative health technologies (IHTs) is challenging in many health systems. Health care payers and health care industry across the European Union (EU) have explored different ways of defining payment for new products. ASCERTAIN addresses the need of patients, physicians, payers, regulators,...
Read more

In Memoriam: Margreet Franken

From: iMTA NEWSLETTER September 2023

With deep sorrow we share the heartbreaking news of the loss of our dear colleague, Margreet Franken. Margreet started her professional career as a nurse, specialised in coronary and intensive care nursing. Over the years, she held various positions in hospitals located in Arnhem, Rotterdam, and Christchurch (New Zealand)....
Read more

ASCERTAIN Project at EHA2023: Improving Access to Innovative Health Technologies in Europe

Prof. Carin Uyl-de Groot Presents ASCERTAIN, Focusing on Affordable CAR-T Cell Therapies and Cancer Care in Eastern Europe

The European Hematology Association (EHA) is dedicated to advancing hematological care, research, and education on a global scale. Through collaborations with medical professionals, national hematology societies, patient groups, the medical industry, and media, EHA strives...
Read more

ASCERTAIN project takes off with great success in Rotterdam

We are excited to share our video showcasing the launch of the ASCERTAIN project in Rotterdam! Our consortium members gathered to kick off this HORIZON-funded initiative with the goal of enhancing access to innovative health technologies in Europe.

Watch our video on Youtube!

ASCERTAIN — from project idea to Grant Agreement

Read the latest Spinverse article about ASCERTAIN

Prof. Dr. Carin Uyl-de Groot from Erasmus University Rotterdam spoke about taking upon the role of Project Coordinator in the consortium project that recently secured funding from Horizon Europe. Together with nine partners, Erasmus School of Health Policy & Management, has launched the ASCERTAIN project...
Read more